Qi I Chen

US Patent:

7915011, Mar 29, 2011

Filed:

Oct 8, 2009

Appl. No.:

12/575550

Inventors:

Qi Chen - Wallingford PA, US
Qiong Cheng - Wilmington DE, US
Kevin Michael Croker - Hockessin DE, US
Thomas Eduard Friedmann - Hockessin DE, US
Kristin Ruebling-Jass - Wilmington DE, US

Assignee:

E.I. du Pont de Nemours and Company - Wilmington DE

International Classification:

C12P 21/00
C12N 1/21

US Classification:

435 691, 43525233

Abstract:

Disrupting the expression of endogenous host cell genes gcvA and spr provides mutant host cells having increased heterologous peptide production. The addition of a genetic modification to the coding region of gene yejM further enhances peptide production and facilitates easier downstream processing. Recombinant host cells are provided as well as methods of using such host cells for heterologous peptide production.

US Patent:

8288137, Oct 16, 2012

Filed:

Nov 15, 2010

Appl. No.:

12/946120

Inventors:

Qi Chen - Wallingford PA, US
Qiong Cheng - Wilmington DE, US
Andrew C. Eliot - Wilmington DE, US
Kristin Ruebling-Jass - Wilmington DE, US

Assignee:

E I du Pont de Nemours and Company - Wilmington DE

International Classification:

C12N 1/21

US Classification:

435146, 43525233, 435159

Abstract:

Recombinant () bacteria that have enhanced acetyl-CoA synthetase activity and the ability to produce glycerol and glycerol-derived products, such as 3-hydroxypropionic acid, methylglyoxal, 1,2-propanediol, and 1,3-propanediol, are described. The recombinant comprise a promoter operably linked to a nucleotide sequence encoding a polypeptide having acetyl-CoA synthetase enzyme activity, wherein the promoter and nucleotide sequence are each independently either native or non-native.

US Patent:

8629243, Jan 14, 2014

Filed:

Aug 16, 2011

Appl. No.:

13/210488

Inventors:

Qi Chen - Wallingford PA, US
Qiong Cheng - Wilmington DE, US
Jian Ping Lai - Wallingford PA, US
Kristin Ruebling-Jass - Wilmington DE, US

Assignee:

E I du Pont de Nemours and Company - Wilmington DE

International Classification:

C07K 14/245

US Classification:

530350, 536 237

Abstract:

Variant sucrose transporter polypeptides that enable faster sucrose utilization in bacteria are described. Additionally, variant or recombinant bacteria comprising these variant sucrose transporter polypeptides, and methods of utilizing the bacteria to produce products such as glycerol and glycerol-derived products are provided.

US Patent:

20120214202, Aug 23, 2012

Filed:

Jun 21, 2011

Appl. No.:

13/164990

Inventors:

Ritu Bhalla - New Delhi, IN
Qi Chen - Wallingford PA, US
Qiong Cheng - Wilmington DE, US
Neeraj Pandey - Haryana, IN
Pierre E. Rouviere - Wilmington DE, US
Kristin Ruebling-Jass - Wilmington DE, US
Annapurna Sachan - Kanpur, IN

Assignee:

E. I. DU PONT DE NEMOURS AND COMPANY - Wilmington DE

International Classification:

C12P 21/06
C12N 1/21

US Classification:

435 691, 43525233

Abstract:

Methods are provided to obtain recombinant microbial cells having at least one genetic modification that increase the buoyant density of a recombinant microbial cell or the buoyant density of inclusion bodies produced within a recombinant microbial cell. Exemplified are genetic modifications that increase the buoyant density of a recombinant microbial cell expressing heterologous peptides and polypeptides. Increasing expression of the genes ysaB, glyQ, glyS or a combination thereof within the recombinant microbial cell produces cells or inclusion bodies having higher buoyant density. A similar effect was achieved by decreasing or disrupting expression of the endogenous gltA gene. Increases in buoyant density render peptide production more efficient with respect to time and costs.

US Patent:

20130045519, Feb 21, 2013

Filed:

Aug 16, 2011

Appl. No.:

13/210550

Inventors:

Qi Chen - Wallingford PA, US
Qiong Cheng - Wilmington DE, US
Jian Ping Lai - Wallingford PA, US
Kristin Ruebling-Jass - Wilmington DE, US

Assignee:

E. I. DU PONT DE NEMOURS AND COMPANY - Wilmington DE

International Classification:

C12P 7/42
C12P 7/20
C12P 7/18
C12N 1/21

US Classification:

435146, 4352523, 43525233, 435159, 435158

Abstract:

Recombinant bacteria having an improved ability to utilize sucrose are provided. These recombinant bacteria have nucleotide sequences encoding sucrose utilization polypeptides integrated into their genome between the yihP gene or its homolog and the yihO gene or its homolog. Additionally, methods of utilizing the recombinant bacteria to produce products such as glycerol and glycerol-derived products are provided.

US Patent:

20130115193, May 9, 2013

Filed:

Nov 8, 2012

Appl. No.:

13/672266

Inventors:

Bristol-Myers Squibb Company - Princeton NJ, US
John A. Bender - Middletown CT, US
Zhong Yang - Southington CT, US
Makonen Belema - North Haven CT, US
Omar D. Lopez - Wallingford CT, US
Qi Chen - Elmhurst NY, US
Gan Wang - Cheshire CT, US
Piyasena Hewawasam - Middletown CT, US

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

C07D 403/14
A61K 31/4545
C07D 401/14
A61K 31/437
C07D 471/04
A61K 31/4985
C07D 487/04
C07D 405/14
A61K 31/498
A61K 31/4178
A61K 31/4375
A61K 31/4709
A61K 31/5377
C07D 413/14
C07D 403/10
A61K 45/06
A61K 31/4184

US Classification:

424 852, 424 857, 514394, 5483054, 514316, 546187, 514303, 546118, 514249, 544350, 5483131, 544353, 514397, 546122, 514300, 546167, 514314, 5142322, 544 82, 5483137, 514 43, 514 44 A

Abstract:

The present disclosure relates to compounds, compositions and methods for the treatment of Hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

US Patent:

20130121957, May 16, 2013

Filed:

May 7, 2012

Appl. No.:

13/465298

Inventors:

Qi Chen - Stamford CT, US
Omar D. Lopez - Wallingford CT, US
John A. Bender - Middletown CT, US
Gan Wang - Cheshire CT, US
Van N. Nguyen - Meriden CT, US
John F. Kadow - Wallingford CT, US
Nicholas A. Meanwell - East Hampton CT, US
Makonen Belema - North Haven CT, US

International Classification:

C07D 403/14
A61K 45/06
A61K 31/4184
A61K 31/5377
A61K 31/4178
C07D 405/14

US Classification:

424 852, 514397, 5483007, 5483121, 514394, 5142322, 544 70, 424 854, 514 43, 514 44 A, 5483131, 424 857, 514293

Abstract:

The present disclosure relates to compounds, compositions and methods for the treatment of Hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

US Patent:

20140018389, Jan 16, 2014

Filed:

Sep 16, 2013

Appl. No.:

14/027531

Inventors:

John A. Bender - Middletown CT, US
Jeffrey Lee Romine - Meriden CT, US
Edward H. Ruediger - Greenfield Park, CA
Carol Bachand - Candiac, CA
Omar D. Lopez - Wallingford CT, US
Qi Chen - Elmhurst NY, US
Makonen Belema - North Haven CT, US
John F. Kadow - Wallingford CT, US
Lawrence G. Hamann - North Grafton MA, US

International Classification:

C07D 417/14
C07D 405/14
C07D 401/14
C07D 403/14
C07D 409/14
C07D 413/14

US Classification:

514316, 5483131, 514397, 548204, 514365, 548236, 514374, 546187, 5483121

Abstract:

This disclosure concerns novel compounds of Formula (I) or as defined in the specification and compositions comprising such novel compounds. These compounds are useful antiviral agents, especially in inhibiting the function of the NS5A protein encoded by Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV related diseases or conditions by use of these novel compounds or a composition comprising such novel compounds.